Page 3 - Dr Reddy’s Laboratories

Dr Reddy's Lab pushes the pedal to touch 1.5 billion patients by FY30

The company also announced that it will work together with the United States Food and Drug Administration (USFDA) to launch the biosimilar rituximab in the US

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition

In India, DRL has an OTC portfolio in the hydration, cough-cold-allergy, and skin care categories

Dr. Reddy's to acquire Haleon's nicotine replacement biz for 500 mn pounds

The acquisition includes Nicotinell, a global leader in the NRT category, and its local market-leading brand names Nicabate, Habitrol, and Thrive

Stocks to Watch, June 14: Voda Idea, Dr Reddy's, Suzlon, Signature Global

Stocks to Watch on Friday, June 14: Vodafone Idea (Vi) has decided to offer a Rs 2,458 crore stake to long-term vendors Nokia and Ericsson in a bid to partially clear outstanding dues

Buzzing stocks, June 10: Order boost for KEC, RVNL; USFDA action on DRL

Stocks to Watch on Monday, June 10: RVNL's joint venture with KRDCL has emerged as the lowest bidder for a project worth Rs 156 crore

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Dr Reddy's Q4 results: Net profit rises 36% to Rs 1,307 cr, revenue up 12%

Q4FY24 results: The company board has recommended a final dividend of Rs 40 per equity share of Rs 5 each for the financial year 2023-24

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results

Indian pharmaceutical giant Dr Reddy's Laboratories is set to witness a single to double digit growth in sales on a year-on-year (Y-o-Y) basis for the fourth quarter of financial year 2023-24 (Q4FY23)

Nestle India Q4FY24 results: Net profit soars 27% to Rs 934 crore

Company to launch Nespresso in India, announces joint venture with Dr. Reddy's Laboratories

Dr Reddy's to market Bayer's second brand of heart failure drug in India

Under the agreement, Dr Reddy's will market Vericiguat under the brand name Gantra

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Dr Reddy's rallies 4%; market cap touches Rs 1 trillion post Q3 results

With this, Dr Reddy's has become the third listed pharmaceutical company to achieve the Rs 1-trillion m-cap feat

Dr Reddy's launches wearable device for drug-free management of migraine

In January this year, Dr Reddy's entered an exclusive agreement with Theranica for the marketing and distribution of Nerivio in India

Dr Reddy's Laboratories Q1 PAT up 18% to Rs 1,402 cr on India, Russia biz

With cash surplus of Rs 4980 crore, pharma major looking at inorganic opportunities

Dr Reddy's Labs Q1FY24 results: Net profit up 18% YoY to Rs 1,402.5 cr

As compared to Rs 959.2 crore in the quarter that ended on March 31, the net profit was up 46%

Dr Reddy's application for biosimilar candidate accepted for USFDA's review

Dr Reddy's Laboratories on Wednesday said its biologics licence application for its proposed biosimilar rituximab candidate has been accepted for a substantive review by the US Food and Drug Administration (USFDA). This closely follows acceptance of the rituximab biosimilar dossier for review by two other regulatory agencies -- the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Rituximab is used to treat certain autoimmune diseases and types of cancer. "This milestone underscores our capability for global clinical development of high-quality biosimilar products for highly regulated and global markets," Dr Reddy's Global Head of Biologics Jayanth Sridhar said in a statement. It also reinforces the potential of the product as a safe and effective treatment option for patients across the globe, he added. Development and commercialisation of biological drugs is an important growth lever for the company's business, Sridhar ...

Dr Reddy's Laboratories forays into new terrain to give 'top-5' aim a shot

Analysts think that these new entries may help the company navigate multiple risks in the Indian branded market

Dr Reddy's completes Phase-I study in proposed biosimilar of tocilizumab

Global Phase III study is being initiated to compare the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product

Dr Reddy's Laboratories QoQ showing catches a cold on weak US sales

While pharma major has maintained its margin guidance, expensive valuations limit upside

Dr Reddy's Laboratories Q4 PAT grows nine-fold riding on US, India biz

For the full year 2022-23, DRL's revenues were up 15 percent to Rs 24,587.9 crore while the PAT grew by 91 percent to Rs 4,506.7 crore